CARM Valuation
Carisma Therapeutics Inc
$
0.294
- Overview
- Forecast
- Valuation
- Earnings
CARM Relative Valuation
CARM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CARM is overvalued; if below, it's undervalued.
Historical Valuation
Carisma Therapeutics Inc (CARM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -1.36. The fair price of Carisma Therapeutics Inc (CARM) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 0.29 USD , Carisma Therapeutics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：0.29
Fair
Undervalued
-0.49
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Carisma Therapeutics Inc. (CARM) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-0.37
EV/EBIT
Carisma Therapeutics Inc. (CARM) has a current EV/EBIT of -0.37. The 5-year average EV/EBIT is -0.45. The thresholds are as follows: Strongly Undervalued below -2.06, Undervalued between -2.06 and -1.25, Fairly Valued between 0.36 and -1.25, Overvalued between 0.36 and 1.16, and Strongly Overvalued above 1.16. The current Forward EV/EBIT of -0.37 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Carisma Therapeutics Inc. (CARM) has a current PS of 0.00. The 5-year average PS is 9.77. The thresholds are as follows: Strongly Undervalued below -17.11, Undervalued between -17.11 and -3.67, Fairly Valued between 23.21 and -3.67, Overvalued between 23.21 and 36.65, and Strongly Overvalued above 36.65. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Carisma Therapeutics Inc. (CARM) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.98. The thresholds are as follows: Strongly Undervalued below -2.44, Undervalued between -2.44 and -1.71, Fairly Valued between -0.25 and -1.71, Overvalued between -0.25 and 0.49, and Strongly Overvalued above 0.49. The current Forward P/OCF of 0.00 falls within the Overvalued range.
0.00
P/FCF
Carisma Therapeutics Inc. (CARM) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.26. The thresholds are as follows: Strongly Undervalued below -3.39, Undervalued between -3.39 and -2.32, Fairly Valued between -0.19 and -2.32, Overvalued between -0.19 and 0.88, and Strongly Overvalued above 0.88. The current Forward P/FCF of 0.00 falls within the Overvalued range.
Carisma Therapeutics Inc (CARM) has a current Price-to-Book (P/B) ratio of -0.23. Compared to its 3-year average P/B ratio of 17.99 , the current P/B ratio is approximately -101.26% higher. Relative to its 5-year average P/B ratio of 17.99, the current P/B ratio is about -101.26% higher. Carisma Therapeutics Inc (CARM) has a Forward Free Cash Flow (FCF) yield of approximately -357.31%. Compared to its 3-year average FCF yield of -188.33%, the current FCF yield is approximately 89.72% lower. Relative to its 5-year average FCF yield of -188.33% , the current FCF yield is about 89.72% lower.
-0.27
P/B
Median3y
17.99
Median5y
17.99
-357.31
FCF Yield
Median3y
-188.33
Median5y
-188.33
Competitors Valuation Multiple
The average P/S ratio for CARM's competitors is 0.44, providing a benchmark for relative valuation. Carisma Therapeutics Inc Corp (CARM) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CARM decreased by 68.90% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -121.37 to -510.59.
The secondary factor is the Revenue Growth, contributed -100.00%to the performance.
Overall, the performance of CARM in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
MIGI
Mawson Infrastructure Group Inc
0.398
USD
-1.00%
ADN
Advent Technologies Holdings Inc
3.370
USD
+3.06%
MCVT
Mill City Ventures III Ltd
6.400
USD
0.00%
IBO
Impact Biomedical Inc
0.669
USD
-1.18%
JFU
9F Inc
2.650
USD
+1.15%
DFLI
Dragonfly Energy Holdings Corp
0.282
USD
0.00%
PMNT
Perfect Moment Ltd
0.490
USD
0.00%
BLIN
Bridgeline Digital Inc
1.320
USD
-0.75%
FAQ
Is Carisma Therapeutics Inc (CARM) currently overvalued or undervalued?
Carisma Therapeutics Inc (CARM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -1.36. The fair price of Carisma Therapeutics Inc (CARM) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 0.29 USD , Carisma Therapeutics Inc is Undervalued By Fair .
What is Carisma Therapeutics Inc (CARM) fair value?
How does CARM's valuation metrics compare to the industry average?
What is the current P/B ratio for Carisma Therapeutics Inc (CARM) as of Sep 23 2025?
What is the current FCF Yield for Carisma Therapeutics Inc (CARM) as of Sep 23 2025?
What is the current Forward P/E ratio for Carisma Therapeutics Inc (CARM) as of Sep 23 2025?
